FedCircuitBlog

Here is an update on recent activity at the Supreme Court in cases decided by the Federal Circuit. With respect to granted cases, a reply brief was filed in Amgen Inc. v. Sanofi, Aventisub LLC, a patent case addressing the enablement requirement. With respect to petitions, a new petition was filed with the Court in a veterans case and another in a pro se case; the government waived its right to respond in a pro se case; a brief in opposition was filed in a patent case; and a reply brief was filed in a trade case. Here are the details. 

Here is an update on recent activity at the Supreme Court in cases decided by the Federal Circuit. The Court recently granted the motion of the Solicitor General leave to participate in oral argument as amicus curiae in Amgen Inc. v. Sanofi, Aventisub LLC, the pending patent case addressing the enablement patentability requirement. With respect to petitions, two new petitions were filed with the Court, one in a pro se case and another in a Merit Systems Protection Board case; the government filed its brief in opposition in a trade case; one amicus brief was filed in a trademark case and three amicus briefs were filed in a patent case (including, interestingly, an amicus brief on behalf of retired federal appellate judges); and the Court denied six petitions in various patent, veterans, and pro se cases. Here are the details. 

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• an article about how the “Federal Circuit refused . . . to rehear a challenge to a Delaware judge’s probe into the financing of patent litigation”;
• another article about “Sanofi and Regeneron on Friday urg[ing] the U.S. Supreme Court to reject Amgen’s arguments that it deserves broad patent coverage on cholesterol drugs”; and
• a blog post examining the reasons why the “Federal Circuit has ordered [Google’s] case moved out of the Western District of Texas (Waco) to the Northern District of California.”

Here is an update on recent activity at the Supreme Court in cases decided by the Federal Circuit. With respect to granted cases, fourteen amicus brief were filed in Amgen Inc. v. Sanofi, Aventisub LLC, a patent case concerning the enablement patentability requirement. With respect to petitions, three new petitions were filed with the Court, one in a veterans case, one in a patent case, and one in a pro se case. Here are the details. 

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• an article about the U.S. International Trade Commission finding “Apple Watches with an electrocardiogram (ECG) function infringe patents belonging to medical device maker AliveCor Inc”;
• another article about Amgen Inc.’s arguments to the Supreme Court that “patents needn’t spell out every possible iteration of an invention in order to be eligible for protection”;
• a third article about “VLSI Technology LLC and Intel Corp . . . agree[ing] to end a patent dispute in Delaware”; and
• a fourth article about “[t]he Federal Circuit . . . order[ing] a California company to defend patent litigation it filed in Texas, as its competitor in optical filters is asking to have the case transferred.”

Here is an update on recent activity at the Supreme Court in cases decided by the Federal Circuit. With respect to granted cases, Amgen filed its opening merits brief in Amgen Inc. v. Sanofi, Aventisub LLC, which concerns patent law’s enablement requirement. With respect to petitions, although no new petitions were filed with the Court, a brief in opposition and a reply brief were filed in patent case concerning inter partes review estoppel, and another reply brief was filed in a veterans case. Here are the details.